GAINESVILLE, Fla., March 9 /PRNewswire/ -- AxoGen, Inc., an early stage medical device company, today has announced their Series B financing of $7.75 million to finance the development of a human allograph for peripheral nerve repair and regeneration.
The Series B round was raised through a consortium of investors led by Cardinal Partners, Accuitive Medical Ventures and De Novo Ventures. Lisa Skeete Tatum, General Partner at Cardinal, Gerard Van Hamel Platerink, Managing Director at Accuitive, and Joe Mandato, Managing Director at De Novo Ventures will join the board.
AxoGen, founded in 2002, is commercializing technology developed at the McKnight Brain Institute of the University of Florida. AxoGen provides surgeons a biological solution to repair and regenerate peripheral nerves, bringing relief and restoring functionality to patients who suffer peripheral nerve injuries. The company brings to this market a unique combination of patented technologies, an experienced management team, and a rich pipeline of new products and technologies to address other nerve injuries. “We are extremely excited about our opportunity to bring this biological solution to patients to restore both sensory and motor function caused by peripheral nerve injuries,” says AxoGen Chief Executive Officer Jamie Grooms.
AxoGen is based in Gainesville, Florida. http://www.AxoGeninc.comhttp://www.cardinalpartners.comhttp://www.amvpartners.com/http://www.denovovc.com/
AxoGen, Inc.
CONTACT: Lisa Skeete Tatum, Cardinal Partners, +1-609-924-6452
Web site: http://www.AxoGeninc.com/